CA2464994A1 - Method and device for the delivery of a substance - Google Patents
Method and device for the delivery of a substance Download PDFInfo
- Publication number
- CA2464994A1 CA2464994A1 CA002464994A CA2464994A CA2464994A1 CA 2464994 A1 CA2464994 A1 CA 2464994A1 CA 002464994 A CA002464994 A CA 002464994A CA 2464994 A CA2464994 A CA 2464994A CA 2464994 A1 CA2464994 A1 CA 2464994A1
- Authority
- CA
- Canada
- Prior art keywords
- microabrader
- skin
- microprotrusions
- substance
- abrading
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000126 substance Substances 0.000 title claims abstract description 112
- 238000000034 method Methods 0.000 title claims abstract description 108
- 238000007790 scraping Methods 0.000 claims abstract description 16
- 210000003491 skin Anatomy 0.000 claims description 225
- 229960005486 vaccine Drugs 0.000 claims description 81
- 210000000434 stratum corneum Anatomy 0.000 claims description 47
- 239000003814 drug Substances 0.000 claims description 36
- 239000004033 plastic Substances 0.000 claims description 29
- 229920003023 plastic Polymers 0.000 claims description 29
- 239000002671 adjuvant Substances 0.000 claims description 24
- 239000010703 silicon Substances 0.000 claims description 22
- 229910052710 silicon Inorganic materials 0.000 claims description 22
- 239000013566 allergen Substances 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 230000000975 bioactive effect Effects 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 238000004891 communication Methods 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims 2
- 230000002238 attenuated effect Effects 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 238000005299 abrasion Methods 0.000 abstract description 60
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 56
- 230000000699 topical effect Effects 0.000 description 42
- 239000013612 plasmid Substances 0.000 description 40
- 230000004044 response Effects 0.000 description 37
- 230000000694 effects Effects 0.000 description 30
- 229960001340 histamine Drugs 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 239000007924 injection Substances 0.000 description 28
- 238000002347 injection Methods 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 22
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 21
- 230000005875 antibody response Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 18
- 238000007918 intramuscular administration Methods 0.000 description 18
- 108060001084 Luciferase Proteins 0.000 description 17
- 239000005089 Luciferase Substances 0.000 description 17
- 229940037003 alum Drugs 0.000 description 17
- 230000003053 immunization Effects 0.000 description 15
- 238000002649 immunization Methods 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 108700008625 Reporter Genes Proteins 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 230000008961 swelling Effects 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 239000008177 pharmaceutical agent Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000002615 epidermis Anatomy 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 206010022000 influenza Diseases 0.000 description 9
- 239000007927 intramuscular injection Substances 0.000 description 9
- 230000036572 transepidermal water loss Effects 0.000 description 9
- 101710154606 Hemagglutinin Proteins 0.000 description 8
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 8
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 8
- 101710176177 Protein A56 Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000000185 hemagglutinin Substances 0.000 description 8
- 206010015150 Erythema Diseases 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 241000193738 Bacillus anthracis Species 0.000 description 6
- 229940021995 DNA vaccine Drugs 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 229940031626 subunit vaccine Drugs 0.000 description 6
- 241000712461 unidentified influenza virus Species 0.000 description 6
- 238000011725 BALB/c mouse Methods 0.000 description 5
- 108010041986 DNA Vaccines Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 230000008591 skin barrier function Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108090000331 Firefly luciferases Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 206010040914 Skin reaction Diseases 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 230000035483 skin reaction Effects 0.000 description 4
- 231100000430 skin reaction Toxicity 0.000 description 4
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 3
- 150000003862 amino acid derivatives Chemical class 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000011685 brown norway rat Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229940023146 nucleic acid vaccine Drugs 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000007390 skin biopsy Methods 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 229960004854 viral vaccine Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010001267 Protein Subunits Proteins 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000000145 adjuvantlike effect Effects 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001142 back Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 229960004931 histamine dihydrochloride Drugs 0.000 description 2
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000003622 mature neutrocyte Anatomy 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000037368 penetrate the skin Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000027317 positive regulation of immune response Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 229960003127 rabies vaccine Drugs 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960001005 tuberculin Drugs 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229910000531 Co alloy Inorganic materials 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229910000599 Cr alloy Inorganic materials 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 229910001182 Mo alloy Inorganic materials 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910000990 Ni alloy Inorganic materials 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079920 digestives acid preparations Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000008902 immunological benefit Effects 0.000 description 1
- 229940026063 imovax Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229940115256 melanoma vaccine Drugs 0.000 description 1
- 238000005459 micromachining Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004218 nerve net Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/54—Chiropodists' instruments, e.g. pedicure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/32—Surgical cutting instruments
- A61B2017/320004—Surgical cutting instruments abrasive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
- Coating Apparatus (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33071301P | 2001-10-29 | 2001-10-29 | |
| US60/330,713 | 2001-10-29 | ||
| US33316201P | 2001-11-27 | 2001-11-27 | |
| US60/333,162 | 2001-11-27 | ||
| PCT/US2002/034504 WO2003051284A2 (en) | 2001-10-29 | 2002-10-29 | Method and device for the delivery of a substance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2464994A1 true CA2464994A1 (en) | 2003-06-26 |
Family
ID=26987410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002464994A Abandoned CA2464994A1 (en) | 2001-10-29 | 2002-10-29 | Method and device for the delivery of a substance |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20030093040A1 (enExample) |
| EP (1) | EP1439870B1 (enExample) |
| JP (1) | JP2005511248A (enExample) |
| CN (1) | CN1662266A (enExample) |
| AT (1) | ATE420676T1 (enExample) |
| AU (1) | AU2002365144A1 (enExample) |
| BR (1) | BR0213686A (enExample) |
| CA (1) | CA2464994A1 (enExample) |
| DE (1) | DE60230894D1 (enExample) |
| ES (1) | ES2319625T3 (enExample) |
| MX (1) | MXPA04003953A (enExample) |
| WO (1) | WO2003051284A2 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6641591B1 (en) | 1999-08-26 | 2003-11-04 | John H. Shadduck | Instruments and techniques for controlled removal of epidermal layers |
| CA2451816A1 (en) * | 2001-06-29 | 2003-01-09 | Becton, Dickinson And Company | Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| US20060018877A1 (en) * | 2001-06-29 | 2006-01-26 | Mikszta John A | Intradermal delivery of vacccines and therapeutic agents |
| US6908453B2 (en) * | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
| JP4469610B2 (ja) * | 2002-02-04 | 2010-05-26 | ベクトン・ディキンソン・アンド・カンパニー | 皮膚アクセス部材 |
| MXPA05000597A (es) | 2002-07-19 | 2005-04-28 | 3M Innovative Properties Co | Dispositivos de microaguja y aparatos de administracion por microaguja. |
| US7422567B2 (en) * | 2002-08-29 | 2008-09-09 | Becton, Dickinson And Company | Microabrader with controlled abrasion features |
| TW200518771A (en) * | 2003-06-30 | 2005-06-16 | Alza Corp | Formulations for coated microprojections containing non-volatile counterions |
| WO2005020912A2 (en) * | 2003-08-25 | 2005-03-10 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
| CN100548228C (zh) * | 2003-11-13 | 2009-10-14 | 阿尔扎公司 | 用于透皮递送的组合物和装置 |
| EP1718452A1 (en) * | 2004-02-23 | 2006-11-08 | 3M Innovative Properties Company | Method of molding for microneedle arrays |
| SE0402100D0 (sv) * | 2004-08-30 | 2004-08-30 | Bonsens Ab | Molded micro-needles |
| EP2995331B1 (en) | 2004-09-10 | 2018-09-05 | Becton, Dickinson and Company | Reconstituting infusion device and method of reconstituting medicament |
| US20070053965A1 (en) * | 2005-02-25 | 2007-03-08 | Gruenenthal Gmbh | Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation |
| CA2620943A1 (en) * | 2005-09-02 | 2007-03-08 | Iomai Corporation | Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs and uses thereof |
| DE102005044737A1 (de) * | 2005-09-19 | 2007-03-29 | Braun Gmbh | Verfahren zum Entfernen von Haaren, Haarentfernungsgerät und Aufsatz hierfür |
| CA2629193C (en) | 2005-11-18 | 2016-03-29 | 3M Innovative Properties Company | Coatable compositions, coatings derived therefrom and microarrays having such coatings |
| WO2007064486A1 (en) * | 2005-11-30 | 2007-06-07 | 3M Innovative Properties Company | Microneedle arrays and methods of use thereof |
| US8048089B2 (en) | 2005-12-30 | 2011-11-01 | Edge Systems Corporation | Apparatus and methods for treating the skin |
| US20090157094A1 (en) * | 2006-01-12 | 2009-06-18 | Nanopass Technologies Ltd. | Device for superficial abrasive treatment of the skin |
| US10172644B2 (en) | 2006-03-29 | 2019-01-08 | Edge Systems Llc | Devices, systems and methods for treating the skin |
| WO2014151104A1 (en) | 2013-03-15 | 2014-09-25 | Edge Systems Llc | Devices, systems and methods for treating the skin |
| US9566088B2 (en) | 2006-03-29 | 2017-02-14 | Edge Systems Llc | Devices, systems and methods for treating the skin |
| EP2021021A2 (en) * | 2006-05-12 | 2009-02-11 | Oklahoma Medical Research Foundation | Anthrax compositions and methods of use and production |
| US20100030100A1 (en) * | 2007-02-06 | 2010-02-04 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle Device For Diagnosis Of Allergy |
| KR20100129269A (ko) | 2008-01-04 | 2010-12-08 | 엣지 시스템즈 코포레이션 | 피부 처리 장치 및 방법 |
| US9056193B2 (en) | 2008-01-29 | 2015-06-16 | Edge Systems Llc | Apparatus and method for treating the skin |
| US20110159035A1 (en) * | 2008-08-01 | 2011-06-30 | Masahiro Goto | S/o type transdermal immunizing agent |
| WO2011005894A1 (en) * | 2009-07-07 | 2011-01-13 | Naya Touch, Inc. | Dermal roller with therapeutic microstructures |
| EP2451367B1 (en) | 2009-07-08 | 2020-01-22 | Edge Systems Corporation | Devices for treating the skin using time-release substances |
| GB201007207D0 (en) * | 2010-04-29 | 2010-06-16 | Univ Cork | Method |
| JP5788019B2 (ja) * | 2011-11-18 | 2015-09-30 | 南部化成株式会社 | 経皮投薬装置 |
| US9044582B2 (en) * | 2012-06-26 | 2015-06-02 | Franklin J. Chang | Apparatus and method for transdermal fluid delivery |
| US10238812B2 (en) | 2013-03-15 | 2019-03-26 | Edge Systems Llc | Skin treatment systems and methods using needles |
| US10194935B2 (en) * | 2013-12-31 | 2019-02-05 | L'oreal | Shear-induced dermal infusion |
| WO2015148688A1 (en) * | 2014-03-26 | 2015-10-01 | Nanomed Skincare, Inc. | Plunger-like mass transportation device for dermal and transdermal delivery of a liquid or solid composition |
| CN107708583B (zh) * | 2014-12-18 | 2020-06-26 | 皇家飞利浦有限公司 | 微晶磨皮装置 |
| EP3795204B1 (en) | 2014-12-23 | 2023-10-25 | HydraFacial LLC | Device for treating the skin using a rollerball |
| US10179229B2 (en) | 2014-12-23 | 2019-01-15 | Edge Systems Llc | Devices and methods for treating the skin using a porous member |
| KR102628349B1 (ko) | 2015-07-08 | 2024-01-24 | 하이드라페이셜 엘엘씨 | 모발 성장을 촉진하기 위한 디바이스, 시스템 및 방법 |
| CN108056845A (zh) * | 2017-12-15 | 2018-05-22 | 深圳清华大学研究院 | 一种侧路腰椎椎间融合器 |
| JP7562515B2 (ja) | 2018-09-24 | 2024-10-07 | クリスタル バイオテック インコーポレイテッド | ネザートン症候群の治療のための組成物及び方法 |
| US11291474B2 (en) | 2020-01-06 | 2022-04-05 | Ed F. Nicolas | Skin treatment tool applicator tip |
| EP4294446A4 (en) * | 2021-02-18 | 2024-12-04 | Agonex Biopharmaceuticals, Inc. | SYSTEMS, DEVICES AND FORMULATIONS FOR THE ADMINISTRATION OF FRACTIONATED HISTAMINE |
| USD1065551S1 (en) | 2021-09-10 | 2025-03-04 | Hydrafacial Llc | Skin treatment device |
| USD1016615S1 (en) | 2021-09-10 | 2024-03-05 | Hydrafacial Llc | Container for a skin treatment device |
| USD1042807S1 (en) | 2021-10-11 | 2024-09-17 | Hydrafacial Llc | Skin treatment tip |
| GB2622416B (en) * | 2022-09-15 | 2025-04-02 | Ndm Tech Ltd | Skin preparation device |
| USD1084369S1 (en) | 2023-02-10 | 2025-07-15 | Hydrafacial Llc | Skin treatment tip |
| DE102024101897A1 (de) * | 2024-01-23 | 2025-07-24 | Gwenaël Bauer | Dermabrasionswerkzeug mit auspressbarem Fluidbehälter |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3289670A (en) * | 1964-03-09 | 1966-12-06 | Milo Bundy Corp | Device for abrading and applying biologicals to the skin of a patient |
| US3556080A (en) * | 1968-04-08 | 1971-01-19 | Lincoln Lab Inc | Skin allergy testing device |
| US3964482A (en) * | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
| OA05448A (fr) * | 1975-10-16 | 1981-03-31 | Manufrance Manufacture Francai | Dispositif vaccinateur multipénétrant. |
| US4270548A (en) * | 1979-09-05 | 1981-06-02 | Aller-Screen, Inc. | Allergy testing method |
| FR2474856A1 (fr) * | 1980-01-31 | 1981-08-07 | Merieux Inst | Dispositif scarificateur |
| FR2498443B2 (fr) * | 1981-01-26 | 1986-03-28 | Merieux Inst | Dispositif scarificateur |
| US4483348A (en) * | 1982-03-25 | 1984-11-20 | Nathan Sher | Skin testing device |
| US4597764A (en) * | 1983-09-28 | 1986-07-01 | Bruce Black | Ossicular replacement prosthesis |
| US4568343A (en) * | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
| US4746515A (en) * | 1987-02-26 | 1988-05-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolaurate |
| AU614092B2 (en) * | 1987-09-11 | 1991-08-22 | Paul Max Grinwald | Improved method and apparatus for enhanced drug permeation of skin |
| TW279133B (enExample) * | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| US5273528A (en) * | 1992-07-10 | 1993-12-28 | Skeen Mikell L | Livestock inoculator |
| DE4307869C2 (de) * | 1993-03-12 | 1996-04-04 | Microparts Gmbh | Mikrostrukturkörper und Verfahren zu deren Herstellung |
| US5679647A (en) * | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5885211A (en) * | 1993-11-15 | 1999-03-23 | Spectrix, Inc. | Microporation of human skin for monitoring the concentration of an analyte |
| US5380337A (en) * | 1994-01-24 | 1995-01-10 | Romaine; Richard A. | Mesh-type skin biopsy appliance |
| US5660680A (en) * | 1994-03-07 | 1997-08-26 | The Regents Of The University Of California | Method for fabrication of high vertical aspect ratio thin film structures |
| JP2551742B2 (ja) * | 1994-05-23 | 1996-11-06 | 三星電機株式会社 | 医薬品投与用皮膚傷形成装置 |
| US5591139A (en) * | 1994-06-06 | 1997-01-07 | The Regents Of The University Of California | IC-processed microneedles |
| US6368333B2 (en) * | 1994-06-29 | 2002-04-09 | Mattioli Engineering Ltd. | V-shaped handpiece for dermabrasion |
| WO1996037155A1 (en) * | 1995-05-22 | 1996-11-28 | Silicon Microdevices, Inc. | Micromechanical device and method for enhancing delivery of compounds through the skin |
| WO1996037256A1 (en) * | 1995-05-22 | 1996-11-28 | Silicon Microdevices, Inc. | Micromechanical patch for enhancing the delivery of compounds through the skin |
| US5958589A (en) * | 1995-07-07 | 1999-09-28 | The United States Of America As Represented By The Secretary Of Agriculture | Starch-based microcellular foams |
| DE19525607A1 (de) * | 1995-07-14 | 1997-01-16 | Boehringer Ingelheim Kg | Transcorneales Arzneimittelfreigabesystem |
| US5658515A (en) * | 1995-09-25 | 1997-08-19 | Lee; Abraham P. | Polymer micromold and fabrication process |
| US6032060A (en) * | 1996-01-25 | 2000-02-29 | 3M Innovative Properties Company | Method for conditioning skin and an electrode by passing electrical energy |
| AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| US5919364A (en) * | 1996-06-24 | 1999-07-06 | Regents Of The University Of California | Microfabricated filter and shell constructed with a permeable membrane |
| DE69722414T2 (de) * | 1996-07-03 | 2004-05-19 | Altea Therapeutics Corp. | Mehrfache mechanische mikroperforierung von haut oder schleimhäuten |
| JP4054381B2 (ja) * | 1996-09-17 | 2008-02-27 | デカ・プロダクツ・リミテッド・パートナーシップ | 移送による薬伝達システム |
| US5910306A (en) * | 1996-11-14 | 1999-06-08 | The United States Of America As Represented By The Secretary Of The Army | Transdermal delivery system for antigen |
| US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US6065864A (en) * | 1997-01-24 | 2000-05-23 | The Regents Of The University Of California | Apparatus and method for planar laminar mixing |
| US5928207A (en) * | 1997-06-30 | 1999-07-27 | The Regents Of The University Of California | Microneedle with isotropically etched tip, and method of fabricating such a device |
| US5931794A (en) * | 1997-10-21 | 1999-08-03 | Pitesky; Isadore | Allergy testing apparatus |
| US6077229A (en) * | 1997-10-21 | 2000-06-20 | Pitesky; Isadore | Allergy testing apparatus |
| US5999847A (en) * | 1997-10-21 | 1999-12-07 | Elstrom; John A. | Apparatus and method for delivery of surgical and therapeutic agents |
| AU739616B2 (en) * | 1997-12-11 | 2001-10-18 | Alza Corporation | Device for enhancing transdermal agent flux |
| US5970998A (en) * | 1998-02-27 | 1999-10-26 | The Regents Of The University Of California | Microfabricated cantilever ratchet valve, and method for using same |
| US6173202B1 (en) * | 1998-03-06 | 2001-01-09 | Spectrx, Inc. | Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue |
| US6106751A (en) * | 1998-03-18 | 2000-08-22 | The Regents Of The University Of California | Method for fabricating needles via conformal deposition in two-piece molds |
| US7004933B2 (en) * | 1998-05-29 | 2006-02-28 | Light Bioscience L.L.C. | Ultrasound enhancement of percutaneous drug absorption |
| US6503231B1 (en) * | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| US6162232A (en) * | 1999-03-18 | 2000-12-19 | Shadduck; John H. | Instruments and techniques for high-velocity fluid abrasion of epidermal layers with skin cooling |
| US6582442B2 (en) * | 2000-02-28 | 2003-06-24 | Dynatronics Corporation | Method and system for performing microabrasion |
| US6256533B1 (en) * | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
| US6312612B1 (en) * | 1999-06-09 | 2001-11-06 | The Procter & Gamble Company | Apparatus and method for manufacturing an intracutaneous microneedle array |
| US6835184B1 (en) * | 1999-09-24 | 2004-12-28 | Becton, Dickinson And Company | Method and device for abrading skin |
| US6331266B1 (en) * | 1999-09-29 | 2001-12-18 | Becton Dickinson And Company | Process of making a molded device |
| ES2238333T3 (es) * | 1999-12-10 | 2005-09-01 | Alza Corporation | Aparato de tratamiento dermico para la administracion prolongada de farmacos por via transdermica. |
| EP1239775B1 (en) * | 1999-12-16 | 2005-03-16 | ALZA Corporation | Device for enhancing transdermal flux of sampled agents |
| US6706032B2 (en) * | 2000-06-08 | 2004-03-16 | Massachusetts Institute Of Technology | Localized molecular and ionic transport to and from tissues |
| MXPA03003303A (es) * | 2000-10-13 | 2004-12-13 | Johnson & Johnson | Retenedor del miembro de microprotrusion para aplicador de impacto. |
| US6821281B2 (en) * | 2000-10-16 | 2004-11-23 | The Procter & Gamble Company | Microstructures for treating and conditioning skin |
| US20020193729A1 (en) * | 2001-04-20 | 2002-12-19 | Cormier Michel J.N. | Microprojection array immunization patch and method |
| US20030135166A1 (en) * | 2001-09-28 | 2003-07-17 | Gonnelli Robert R. | Switchable microneedle arrays and systems and methods relating to same |
-
2002
- 2002-10-29 WO PCT/US2002/034504 patent/WO2003051284A2/en not_active Ceased
- 2002-10-29 US US10/282,231 patent/US20030093040A1/en not_active Abandoned
- 2002-10-29 MX MXPA04003953A patent/MXPA04003953A/es active IP Right Grant
- 2002-10-29 EP EP02803296A patent/EP1439870B1/en not_active Expired - Lifetime
- 2002-10-29 BR BRPI0213686-4A patent/BR0213686A/pt not_active IP Right Cessation
- 2002-10-29 JP JP2003552217A patent/JP2005511248A/ja not_active Withdrawn
- 2002-10-29 ES ES02803296T patent/ES2319625T3/es not_active Expired - Lifetime
- 2002-10-29 CA CA002464994A patent/CA2464994A1/en not_active Abandoned
- 2002-10-29 AU AU2002365144A patent/AU2002365144A1/en not_active Abandoned
- 2002-10-29 CN CN028214471A patent/CN1662266A/zh active Pending
- 2002-10-29 DE DE60230894T patent/DE60230894D1/de not_active Expired - Lifetime
- 2002-10-29 AT AT02803296T patent/ATE420676T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1439870B1 (en) | 2009-01-14 |
| EP1439870A2 (en) | 2004-07-28 |
| ATE420676T1 (de) | 2009-01-15 |
| WO2003051284A2 (en) | 2003-06-26 |
| CN1662266A (zh) | 2005-08-31 |
| US20030093040A1 (en) | 2003-05-15 |
| MXPA04003953A (es) | 2004-06-18 |
| JP2005511248A (ja) | 2005-04-28 |
| EP1439870A4 (en) | 2006-03-01 |
| AU2002365144A1 (en) | 2003-06-30 |
| ES2319625T3 (es) | 2009-05-11 |
| DE60230894D1 (enExample) | 2009-03-05 |
| WO2003051284A3 (en) | 2004-01-29 |
| BR0213686A (pt) | 2006-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1439870B1 (en) | Device for the delivery of a substance | |
| EP1289599B1 (en) | Applicator having abrading surface coated with substance to be applied to skin | |
| US7582069B2 (en) | Method and device for the delivery of a substance | |
| Kim et al. | Delivery systems for intradermal vaccination | |
| JP4382356B2 (ja) | 微小突起アレイ免疫感作貼付剤および方法 | |
| EP1392389B1 (en) | Microprojection array having a beneficial agent containing coating | |
| JP2004531578A (ja) | ワクチンおよび遺伝子治療剤のマイクロカニューレによる皮内送達 | |
| AU2001261757A1 (en) | Applicator having abrading surface coated with substance to be applied to skin | |
| CA2619452A1 (en) | Coatable transdermal delivery microprojection assembly | |
| EP3251722B1 (en) | Microprojection array having a beneficial agent containing coating and method of forming the coating thereon | |
| AU2002327186A1 (en) | Intradermal delivery of vaccines and gene therapeutic agents via microcannula | |
| AU2007203302A1 (en) | Microprojection array immunization patch and method | |
| ZA200309003B (en) | Microprojection array immunization patch and method. | |
| AU2002311839A1 (en) | Microprojection array immunization patch and method | |
| NZ538043A (en) | Composition having a beneficial agent for forming a solid coating on microprojections array |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |